2 shares to buy in February for healthy dividends

Charlie Carman examines a pair of healthcare shares he’ll buy in February for passive income, thanks to their rock-solid dividend yields.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The biotech sector is one of my favourites in which to invest. Non-cyclical demand for medicines and the possibility for shareholders to benefit from exciting clinical breakthroughs are appealing factors. Accordingly, I think there are plenty of dividend shares to buy in this area of the stock market that have potential for good long-term returns.

Two pharma stocks I already own that I’m buying more of this month are FTSE 100 constituent GSK (LSE: GSK) and S&P 500 constituent Johnson & Johnson (NYSE: JNJ).

Let’s explore the outlook for each company in turn.


The GSK share price fell 10% over the past year. However, there are signs of a recovery after strong earnings results. The stock currently yields 6.05%.

Climbing 13% year on year to £29.3bn, the firm’s full-year sales exceeded expectations. I’m particularly encouraged by double-digit annual revenue growth across several divisions, including speciality medicines (+37%), oncology (+23%), and HIV (+20%).

The pharma giant signalled shareholders may benefit from improved margins. It predicts a 10-12% adjusted operating profit rise and a 12-15% earnings per share (EPS) uplift. These numbers add credibility to CEO Emma Walmsley’s claim that 2022 was a “landmark year” for the business.

In addition, passive income investors will note the company’s progressive dividend policy remains unchanged, guided by a 40-60% payout ratio. An expected dividend of 56.5p per share makes this one of the highest-yielding FTSE 100 stocks in the sector.

The firm faces risks from competition, particularly companies that have invested heavily in mRNA technologies, like Moderna and Pfizer. Both businesses are targeting an RSV vaccine this year. Recently, Moderna announced its candidate vaccine was 84% effective at preventing symptoms in older adults in a late-stage trial.

GSK has cited its potential new RSV vaccine as a growth area. The company could face a tough fight for market share. Nonetheless, this stock looks attractively valued compared to its rivals, in my view, with a price-to-earnings ratio of just 4.15.

Johnson & Johnson

The Johnson & Johnson share price fell 4.5% over the past 12 months. The dividend yield is 2.77%.

The firm is a true dividend aristocrat. It’s enjoyed a 59-year dividend growth streak and hasn’t missed a dividend payment in over a century. Although shareholder payouts aren’t guaranteed, this company’s dividend is about as safe as it gets.

It’s one of only two US companies with an AAA-credit rating, alongside Microsoft. This means it has a very low bankruptcy risk, even in a severe recession. The firm has a strong drugs pipeline and a diverse product mix. It manufactures vaccines, medical devices, and consumer healthcare products.

Robust product demand makes Johnson & Johnson an inflation-resistant stock in my view. However, the company also faces looming settlements for potentially billions of dollars in restitution payments.

Over 40,000 lawsuits have been filed alleging that the group’s talcum powder products caused cancer. A US court recently blocked the business from using a legal manoeuvre to divide the company and file for bankruptcy in the proceedings, although Johnson & Johnson plans to appeal the decision.

Ongoing legal difficulties could limit further share price growth. Despite the risks, a solid history of good returns, a resilient balance sheet, and reliable dividends make this stock a buy for me.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Charlie Carman has positions in GSK, Johnson & Johnson and Microsoft. The Motley Fool UK has recommended GSK and Microsoft. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

The National Grid share price nosedived 21% in 2 days! Is it time to take advantage?

The National Grid share price tumbled after the company surprised shareholders by revealing plans to raise more money via a…

Read more »

Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
Dividend Shares

How I’d try to ironclad my second income before interest rates fall

Jon Smith explains a couple of tactics he's looking to implement in his dividend portfolio to try and protect his…

Read more »

Investing Articles

The FTSE 100 still looks cheap to me. But don’t just take my word for it!

The FTSE 100 (INDEXFTSE:UKX) has increased 7.5% since the start of 2024. But I think there’s evidence to suggest that…

Read more »

Investing Articles

What should the Vodafone share price be? Here are 3 possible answers

Our writer uses a number of popular financial measures to come up with an estimate of a fair value for…

Read more »

Investing Articles

Here’s how much I’d have if I’d bought 1,000 shares in this FTSE 100 defence stock 5 years ago

I could have made a pretty penny investing in this leading FTSE 100 defence stock. Now I’m looking at a…

Read more »

Investing Articles

1 potential millionaire-maker UK stock I’d like to buy for the long haul

For long-term investors, here’s 1 UK stock to consider buying right now with the potential to help power a growth…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

These cheap UK shares look way too good to ignore right now

With the UK stock market reaching new highs recently, this Fool plans to grab these two remaining cheap shares before…

Read more »

Young Woman Drives Car With Dog in Back Seat
Investing Articles

This unloved UK stock could rise 120%, according to a City broker

Some City analysts reckon a once-popular UK stock can recover from its massive recent decline and go on to more…

Read more »